News Hub | News Direct

All Industries


Article thumbnail News Release

Alvarez & Marsal Report: Top Private Brand Retailers Outperform the Market: 7 out of Top 10 Retailers by Grocery Dollar Share Are Top Private Brand Players

Alvarez & Marsal Consumer and Retail Group

· U.S. Private Label spending is 20% of total market, projected to rise to 24% by 2030 · Top 4 Private Brand retailers had 144% stock price growth in past 5 years · Over 250 new stores have been opened by top Private Brand retailers in the past year Global professional services firm Alvarez & Marsal’s Consumer and Retail Group (A&M CRG) has released its latest report, Accelerate your Private Brand journey to win with customers and shareholders, which looks at how the Private Label market is accelerating even amid slower total grocery market growth, and what retailers need to do to gain and maintain success with their private brands. The report lays out the case for private label traction as a strategic imperative for grocers and provides examples of the ways in which prominent Private Brand retailers have built stronger loyalty and advocacy with their customers while delivering superior returns for their shareholders. “There’s a strong correlation between the most successful private brand grocers and their market share and financial performance,” noted Marco Valentini, Managing Director at Alvarez & Marsal’s Consumer and Retail Group. “The best players act differently from the rest of the pack. Their C-level executives are committed to growing their own brands and driving differentiation through them. Chief Merchants treat their Private Brands with the same priority and attention as they do National Brands. Marketing and branding efforts are aimed at elevating and differentiating products and increasing overall customer awareness and advocacy of their brands. Finally, product innovation cycles need to reflect the yearly cadence of line reviews and retailers must be able to constantly innovate and update their ‘Own Brand’ products.” The report lays out key enablers to winning with private brands, and the benefits of having a Private Brand strategy, including: · Value perception: Private Brand products should be 30 to 50% less expensive than National Brands and provide same or better quality. The majority of consumers cite value as a key driver of purchase. · Product innovation/differentiation: Private Brand products can be tailored to align with customer demographics and preferences. The second most important attribute that drives purchase of private brands is quality/taste. · Margin management: Private Brand margins typically surpass those of National Brands and the individual product should provide the same or better unit economics (“penny profit”) than their National Brand equivalents. Private Brands are a very effective way to drive value for customers in addition to price and promotion investment, which often dilute margins. · Brand development: More than 8 in 10 shoppers make decisions based on brand trust, so developing private label brands that resonate with consumers and provide strong advocacy is critical. Successful Private Brands can drive positive impact to retailers’ overall banner brand perception. · Sustainable sourcing: Direct control over product development, packaging, sourcing and supply chain can support specific sustainability goals. This is an important factor, especially for Gen Z and Millennial shoppers. "For many grocery retailers today, the lack of a comprehensive Private Brand strategy means that they’ll get left behind,” said John Clear, Senior Director in Alvarez & Marsal’s Consumer and Retail Group. “To unlock the value of private label, grocers need to have a clear plan in place: a differentiated brand architecture and consistent positioning across categories; scalable processes and innovation capabilities that will ensure their success is repeatable.” To download a pdf of Accelerate your Private Brand journey to win with customers and shareholders, please visit: https://alvarezandmarsal-crg.com/insight/accelerate-your-private-brand-journey-to-win-with-customers-and-shareholders/ The Alvarez and Marsal Consumer and Retail Group (CRG) is a management consulting firm that tackles the most complex challenges and advances its clients, people, and communities toward their maximum potential. CRG combines the best of A&M’s broader firm bias toward action and practicality with deep consumer and retail industry experience. CRG partners with businesses across a wide range of categories including Grocery, Mass, Convenience, Discount/Dollar, Wholesale/Distribution, Food & Beverage, Beauty & Personal Care, and Apparel & Footwear to drive significant performance improvement. Contact Details David Schneidman dschneidman@alvarezandmarsal.com Company Website https://www.alvarezandmarsal.com/industries/retail/retail

September 10, 2024 02:00 PM Eastern Daylight Time

Article thumbnail News Release

National Land Realty Finds Acreage Prices Remain Stable Through First Semester

National Land Realty

National Land Realty (NLR), the nation's fastest-growing land brokerage firm specializing in farm, ranch, country estates, timber, recreational, and commercial development properties, has released its latest data on land sales across the United States. The report draws from NLR’s network of over 400 agents and brokers in 48 states to provide a year-to-date analysis of Q1 and Q2 agricultural land sales for 2024. It demonstrates stability in the national aggregate for average price per acre (PPA), while highlighting notable trends within outliers like Louisiana, Florida, and California. National Aggregate The data from NLR’s latest report showed that the average price per acre across the country remained relatively stable, having increased by only about 5% nationally. This comes in the wake of significant farmland appreciation over the past few years, with many parts of the country seeing record prices for farmland in 2023. “Land prices have remained high in spite of increased input costs and interest rates, indicating significant demand across the country for irrigated and available farmland. This is largely due to massive consumer demand for produce, meat, dairy, and feed,” said Ronnie Richardson, CEO at NLR. “While further increases are unlikely for the moment, I believe these values will remain strong for the foreseeable future—barring extensive drought, natural disasters, or an industry-shaking event akin to the COVID-19 pandemic.” Louisiana According to NLR, the data found that the average price per acre in Louisiana decreased by $10,866, primarily due to some of the larger landowners beginning to divest themselves of some farmland holdings. “Louisiana is largely farmland, where land values are influenced by the same forces as elsewhere: supply and demand. Price adjustments occur when production costs rise and commodity prices fall,” said Richardson. “Even with a slight decrease in price per acre, purchasing land remains attractive as divestments create opportunities for buyers to capitalize on economies of scale.” California Data revealed that California's average price per acre dropped by $12,226 over the past year—a significant 27% decline. This decrease is likely driven by a combination of high interest rates and low commodity prices for popular crops like almonds and walnuts. Since prices are relatively high in California overall, percentage-based factors like tax or interest-rate hikes hit the California market harder than they do other states. “Reports of an exodus from California real estate have little implications for the agricultural market, which remains generally unaffected by geopolitics. Taxes and interest rates are far more likely to influence the market,” said Richardson. “We do have a couple of large institutional investors looking to exit the California farmland market, but there are no buyers thus far. They may need to adjust their prices to match demand if they are serious about liquidating. With the average price per acre already down, I'd recommend watching the market closely and holding off on purchases for now." Florida In Florida, the average price per acre surged by $24,000 from 2023 to 2024, reflecting a remarkable 118% increase. This significant rise is driven primarily by the soaring demand for land in the state over the past year. Florida remains one of the top destinations for people moving to different states in the US, meaning this demand for available land in Florida isn’t likely to change anytime soon. “It's the same issue here: supply and demand,” said Richardson. “Even though the price per acre is up, I would still recommend buying land in Florida as demand continues to rise. I would focus on transitional properties in particular as more people continue to move into the state. The key to Florida is simple: demand is driving everything." Annex About National Land Realty National Land Realty (NLR) is the nation’s fastest growing real estate land brokerage company specializing in farm, ranch, country estates, timber, recreational, and commercial development properties. Highly regarded for its proprietary land touring technology, Land Tour 360 ®, as well as its GIS land mapping system, LandBase™, which catalogs land data in extremely detailed ways, the company makes it easy to view and zero in on the right property in the right place. Founded in Greenville, S.C. in 2007, NLR has more than 80 offices in 40 states. To learn more visit www.nationalland.com or call (855) 384-5263. Methodological Note The data in the report was derived from a compilation of land sales data provided by National Land Realty’s network of agents across the United States. The report compares 2023 sales data to sales data from the first half of 2024. For the first half of 2024, the data is based on 6,963 land transactions. Note to the editors A table with data for all states where National Land operates is available in the annex. A headshot of Ronnie Richardson, the company logo, and a map illustrating the states where land values are appreciating or depreciating the most can be accessed via this link. Contact Details Razor Sharp PR Jo Detavernier +1 210-803-2097 jo@razorsharppr.com Company Website https://nationalland.com/

September 10, 2024 09:30 AM Central Daylight Time

Article thumbnail News Release

TRON, Tether, and TRM Labs Establish First-Ever Private Sector Financial Crime Unit to Combat Crypto Crime

TRON DAO

Singapore — September 10, 2024 — TRON, Tether, and TRM Labs today announced they have joined forces to establish the T3 Financial Crime Unit (T3 FCU), a first-of-its-kind initiative aimed at facilitating public-private collaboration to combat illicit activity associated with the use of USDT on the TRON blockchain. This novel collaboration brings together the anti-financial crime expertise of TRM Labs, a leading blockchain intelligence firm; the technical expertise of TRON, a leading global blockchain and DAO; and external investigations team at Tether, the largest company in the digital asset industry, to create a safer and more secure crypto community for all. In the weeks since launch, the initiative, in collaboration with law enforcement, facilitated the freezing of over USDT 12 million in funds associated with a blackmail scam, an investment fraud scheme, and others. Police are aware of at least 11 victims impacted by the scams and expect to identify additional victims as the investigations unfold. Stablecoins like USDT serve as the backbone of the digital asset industry, providing a stable store of value and enabling seamless movement of funds between platforms. With over $117 billion USD in market capitalization and more than 50% of its circulating supply running on the TRON blockchain, USDT is integral to facilitating transactions and liquidity. However, the same features that make USDT on TRON attractive to legitimate users — low fees, lack of volatility, and ease of use — have also drawn the attention of scammers, terrorist financiers, and other threat actors. And as the TRON blockchain's popularity and user base grow, drawn by its high throughput and low transaction costs, so too does its uninvited exposure to these criminal elements. The establishment of the T3 FCU represents a significant step towards impeding the ability of malicious actors to launder and utilize the proceeds of crime, safeguarding the integrity of the TRON blockchain. As part of the collaboration, TRM will provide ongoing support to TRON and Tether in identifying transactions that have a connection to alleged illegal activities such as terrorism, sanctions evasion, theft, hacking, cybercrime, and fraud. TRM will leverage its proprietary technology as well as its global network of expert investigators to generate intelligence. The work will support TRON’s and Tether’s efforts to disrupt criminal activity and aid collaborations with law enforcement around the world. By collaborating to proactively identify and disrupt illicit activity, the T3 FCU aims to promote security and prosperity across the TRON network and beyond. “TRON originated with the belief that technology can be used for good and to empower people across the globe,” said Justin Sun, founder of the TRON blockchain. “By collaborating with TRM Labs and Tether, TRON is helping to ensure that blockchain technology is used to make our world a better place, and sends a clear message that illicit activity is not welcome in our industry.” "At Tether, safeguarding the integrity of the blockchain ecosystem is a top priority and a responsibility we embrace with being a key player in the digital asset space. This commitment drives us to take proactive measures in helping maintain the security and trustworthiness of the ecosystem," said Paolo Ardoino, CEO of Tether. "We’re proud to have worked with TRM Labs and TRON in this pioneering effort. This collaboration underscores our dedication to joining with industry leaders and law enforcement to combat illicit activity, ensuring a secure environment for all users." “As adoption of stablecoins continues to rise, it’s critical that key industry players proactively evolve their capabilities to combat illicit activity and ensure a safe and secure environment,” said Chris Janczewski, head of global investigations at TRM Labs. “TRM is proud to collaborate with TRON, Tether, law enforcement, and others who are committed to helping build a safer blockchain industry for all.” About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by Justin Sun, the TRON network has continued to deliver impressive achievements since MainNet launch in May 2018. July 2018 also marked the integration of BitTorrent, a pioneer in decentralized Web3 services, boasting over 100 million monthly active users. The TRON network has gained incredible traction in recent years. As of August 2024, it has over 247 million total user accounts on the blockchain, more than 8 billion total transactions, and over $22 billion in total value locked (TVL), as reported on TRONSCAN. In addition, TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin across the globe, overtaking USDT on Ethereum since April 2021. The TRON network completed full decentralization in December 2021 and is now a community-governed DAO. Media contact: press@tron.network About Tether Tether is a pioneer in the field of stablecoin technology, driven by an aim to revolutionize the global financial landscape. With a mission to provide accessible and efficient financial, communication, artificial intelligence and energy infrastructure. Tether enables greater financial inclusion, and communication resilience, fosters economic growth, and empowers individuals and businesses alike. As the creator of the largest, most transparent, and liquid stablecoin in the industry, Tether is dedicated to building sustainable and resilient infrastructure for the benefit of underserved communities. By leveraging cutting-edge blockchain and peer-to-peer technology, it is committed to bridging the gap between traditional financial systems and the potential of decentralized finance. Media contact: press@tether.to About TRM Labs TRM Labs provides blockchain intelligence to help law enforcement and national security agencies, financial institutions, and cryptocurrency businesses detect, investigate, and disrupt crypto-related fraud and financial crime. TRM’s Blockchain Intelligence platform includes solutions to follow the money, identify illicit activity, build cases, and construct an operating picture of threats. TRM is trusted by a growing number of leading agencies worldwide who rely on TRM for their blockchain intelligence needs. TRM is based in San Francisco, CA, and is hiring across engineering, product, sales, and data science. To learn more, visit www.trmlabs.com. Media contact: press@trmlabs.com Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

September 10, 2024 10:15 AM Eastern Daylight Time

Image
Article thumbnail News Release

Anthony Milewski Shares His Insights on Junior Mining Stocks

MarketJar

The Oregon Group continues to lead the conversation in market speculation with its latest insights into the junior mining sector. In the latest "Greed, Guts and Glory" newsletter, founder Anthony Milewski delves into the unique challenges and opportunities within this high-stakes arena, framing junior miners as a bold and strategic choice in a high-stakes environment, comparable to the complexities of trading options. Available on The Oregon Group platform, this newsletter is more than just a publication—it's a community. "Greed, Guts and Glory" is designed to build a network of like-minded speculators, offering a space for exchanging ideas, refining strategies, and celebrating market successes. The Strategic Insight: Junior Miners as Options Trades In the volatile world of commodities, success often depends on timing and strategy. Anthony Milewski, with his decades of experience in the sector, offers a fresh perspective on investing in junior mining companies. Instead of viewing these stocks as traditional equity investments, Milewski suggests that they should be approached as "call options" on large, out-of-the-money deposits. Much like options, junior mining stocks come with a significant amount of risk, primarily due to their reliance on commodity price movements and the inevitable need for capital raises. However, this risk also brings the potential for outsized rewards when the timing is right. The key, as Milewski emphasizes, is understanding the underlying commodity and recognizing the signs of an impending market shift. Understanding the Risks and Rewards The junior mining space is notoriously speculative. With only one in three thousand exploration projects ever evolving into a viable mine, the odds are clearly stacked against investors. However, as Milewski points out, it’s this very risk that creates the possibility for exponential returns. For those willing to embrace this high-risk, high-reward dynamic, the approach is clear: buy the dream, capitalize on a favorable commodity move, and sell at the peak of market enthusiasm. This strategy mirrors the approach taken by options traders, where timing is everything, and the ability to exit before the value erodes is crucial. The Importance of Commodity Cycles Central to this strategy is the understanding of commodity cycles. As Milewski notes, the value of a junior mining stock is heavily influenced by the price of the underlying commodity. At a certain price point, any project can become viable, but below that threshold, even the most promising projects may falter. By recognizing where a specific commodity is in its cycle, investors can better gauge when to enter and exit positions in junior mining stocks. This timing, combined with a deep understanding of the project’s potential and its leverage to the commodity, forms the crux of successful speculation in this space. Leveraging Low-Grade Deposits for High Returns Milewski also highlights the potential hidden in large, low-grade deposits that are often overlooked by the market. These projects, while not immediately attractive due to their lower grades, can become highly valuable as commodity prices rise. This leverage to commodity price movements is where significant wealth can be generated. Robert Friedland, a prominent figure in mining, famously stated that “grade doesn’t matter,” a sentiment echoed by Milewski. He argues that it’s just as challenging to permit and develop a small project as it is a large one, so if you’re going to invest, it’s wise to focus on the bigger opportunities with the potential for substantial returns. Timing the Market: A Fine Art Ultimately, the success of this strategy hinges on timing the market correctly. Entering too early can lead to erosion of value due to ongoing capital raises, while waiting too long may mean missing out on the rapid appreciation that can occur as commodity prices shift. The Oregon Group ’s approach is to constantly evaluate these opportunities, focusing first on the commodity and then on the companies with the best leverage to that commodity. While the path to success in junior mining stocks is fraught with risk, the potential rewards make it a compelling consideration for those with the experience and insight to navigate it. A New Perspective on Junior Mining Investments The Oregon Group ’s latest insights offer a compelling framework for understanding and investing in the junior mining sector. By approaching these stocks as options trades, with a clear focus on timing and commodity leverage, investors can position themselves to potentially reap significant rewards. However, as with all speculative investments, the importance of discipline, timing, and a thorough understanding of the market cannot be overstated. For those ready to explore this high-risk, high-reward strategy, staying informed and connected with experts like Anthony Milewski and The Oregon Group will be crucial to navigating this complex market successfully. For more insights, visit The Oregon Group's website at www.theoregongroup.com or follow them on LinkedIn and Twitter. To stay connected with Anthony Milewski, visit www.anthonymilewski.com or follow him on Twitter/X. Follow The Oregon Group on LinkedIn and Twitter. Disclaimer  1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.  2) The Article was issued on behalf of and sponsored by, The Oregon Group. Market Jar Media Inc. has or expects to receive from The Oregon Group’s Digital Marketing Agency of Record (Native Ads Inc) one thousand five hundred USD for this article.  3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy  4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com  5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.  6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding The Oregon Group.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to The Oregon Group.’s industry; (b) market opportunity; (c) The Oregon Group’s business plans and strategies; (d) services that The Oregon Group intends to offer; (e) The Oregon Groups milestone projections and targets; (f) The Oregon Group’s expectations regarding receipt of approval for regulatory applications; (g) The Oregon Group’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) The Oregon Group’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute The Oregon Group’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) The Oregon Group’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) The Oregon Group’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) The Oregon Group’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of The Oregon Group to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) The Oregon Group’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact The Oregon Group’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing The Oregon Group’s business operations (e) The Oregon Group may be unable to implement its growth strategy; and (f) increased competition.  Except as required by law, The Oregon Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does The Oregon Group nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither The Oregon Group nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.  7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of The Oregon Group or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of The Oregon Group or such entities and are not necessarily indicative of future performance of The Oregon Group or such entities.  8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

September 10, 2024 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

PathAI Launches MET Predict on AISight to Enhance NSCLC Assessments

PathAI

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict † on the AISight Ⓡ † Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image. NSCLC accounts for approximately 85% of lung cancers 1, with 3–4% of these cases involving METex14 2. Today, approved targeted therapies are available for patients with NSCLC who harbor METex14 mutations. Additionally, MET amplification occurs in 1–6% of NSCLC cases 3 and is emerging as a potential biomarker in lung cancer. Traditional molecular testing for MET alterations such as exon 14 skipping or amplification is often hindered by high costs, time- and tissue-consuming procedures, and the need for specialized equipment and trained personnel. These factors limit its accessibility and scalability, prompting the need for more efficient and cost-effective methods to assess MET alterations. “The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By providing rapid and precise biomarker insights directly from H&E images, MET Predict equips pathologists with the essential information needed to drive timely and accurate NSCLC evaluations.” MET Predict has the potential to significantly improve the efficiency of biomarker evaluation and molecular testing paradigms. The algorithm identifies >90% of MET altered tumors while additionally providing insights that may preserve tissue in 30% of cases where the likelihood of MET alteration is low. With the addition of MET Predict, AISight expands its toolset with the latest technology to assist pathologists in lung cancer assessments. This innovation addresses a crucial gap in pathology labs — the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples. †:MET Predict and AISight are for Research Use Only. Not for use in diagnostic procedures. References: 1 American Cancer Society. Key Statistics for Lung Cancer. https://www.cancer.org/cancer/lung-cancer/about/what-is.html​ 2 Frampton, G. M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer discovery, 5(8), 850-859.​ 3 Wolf J., et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. PMID: 32877583 About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions, dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 10, 2024 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

‘Play’ The Market: The Thrill Of Gamified Trading

Benzinga

By Johnny Rice, Benzinga Trent Hoerr, CEO of BullRush was recently a guest on Benzinga’s All-Access. BullRush is a competitive gamified trading platform, blending fantasy sports and trading into a gamified interactive trading competition. Participants from around the world compete against each other in a variety of trading competitions that center on CFD, Forex, and other securities as well as trivia tournaments and challenges. The platform rapidly gained traction after its beta release on July 10, gaining 13,700 traders from over 150 countries. Watch the full interview here: Featured photo by Giorgio Trovato on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 09:05 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

This Company Is Betting On Innovation To Make A Splash In Multiple Healthcare Markets And It Hit Multiple Milestones This Year

Benzinga

By James Blacker, Benzinga Therma Bright Inc. (OTC: TBRIF), a growing player in the healthcare industry, is making visible strides with its diverse portfolio of innovative medical devices and diagnostic solutions designed to address unmet clinical needs. With its flagship product the Venowave VW5, a product designed to enhance blood circulation, Therma Bright is aiming to capitalize on a deep vein thrombosis (DVT) treatment market expected to grow to $1.62 billion by 2032. Beyond this, the company’s ambitions expand to developing cutting-edge technology to tackle a variety of health challenges, from respiratory disease management to pain relief. Over 2024, Therma Bright secured multiple milestones that indicate the growing attention it is receiving. The Venowave: A Potential Game-Changer in DVT Prevention The Venowave VW5 is an FDA-approved circulation booster designed to improve circulation in the lower extremities. Worn on the calf, the lightweight device stimulates blood flow with wave-like motions that massage the leg, forcing blood from the feet and legs back to the heart and preventing the formation of blood clots. This is particularly effective in cases of DVT, a condition that affects up to 900,000 people in the U.S. and that, if left untreated, can lead to serious complications such as a pulmonary embolism. Beyond just DVT, the Venowave has a range of other healthcare applications, such as managing symptoms of post-thrombotic syndrome, preventing primary thrombosis and treating lymphedema. In an encouraging sign for the product, Therma Bright announced on 27 August that it has secured a nationwide U.S. distribution partner for Venowave. Subject to the success of an initial sales program, this unnamed partner has committed to acquiring inventory worth $2.38 million. Also in August, Therma Bright received the permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Department of Health & Human Services' Centers for Medicare and Medicaid Services (CMS). This crucial designation increases the product’s credibility and could be a key catalyst to help propel Therma Bright to a leadership position in the DVT treatment market. Preva®: Clot Retrieval For Stroke Treatment The global coronary stents market was estimated to be $8.82 billion in 2022 and is expected to grow at a compound annual growth rate of 7.82% to reach $16.14 billion by 2030. Positioning itself to take a share of this growing market, Therma Bright has added to its diverse portfolio of late-stage products by investing in Inretio, the developer of the Preva® clot-retrieval device. The company hopes this device will revolutionize ischemic stroke treatment by improving effectiveness and preventing complications during thrombectomy procedures. The technology, which recently completed its third successful human trial, promises to offer a new approach to clot retrieving that reduces the need for repeated maneuvers and minimizes the risk of embolization. With more than 690,000 ischemic stroke patients in the U.S. each year, this potentially game-changing device could be the breakthrough in clot retrieval needed to significantly improve their lives. Another Growth Opportunity In The COPD Market Another of Therma Bright’s ventures that may hold promise is its stake in InStatin, a company developing inhaled statin therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). Unlike traditional oral therapies, InStatin targets the lungs directly, and the company hopes to provide a more effective treatment option for a range of respiratory conditions that affect millions of people worldwide. With the COPD market alone estimated to be worth over $16 billion annually, Therma Bright could stand to benefit from InStatin’s growth trajectory as its therapies advance through pre-clinical trials. Therma Bright previously owned a 17% stake in InStatin, but this percentage is set to increase as the company recently announced that it has expanded its investment. More In The Pipeline Therma Bright’s innovation pipeline doesn’t stop there. Other products in development include a Digital Cough Test app developed in partnership with AI4LYF. The app uses AI to monitor respiratory diseases based on the sound of a person’s cough. The cough data is reviewed by a doctor via an AI dashboard who can use the information to then treat the patient. Other products in Therma Bright’s portfolio include the Benepod™ Hot & Cold Contrast Therapy Device for Pain Relief, the AcuVid™ COVID-19 Rapid Antigen Test Solution, InterceptCS™ for at-home cold sore prevention and the TherOZap™ thermal therapy for insect bite relief. Why You May Want To Keep An Eye On Therma Bright With the global DVT market expected to reach $1.5 billion by 2032 and other innovations like the Preva® device and inhaled statins addressing multi-billion-dollar markets, Therma Bright could be well-positioned to capture a significant market share in multiple growing markets. Investors may want to keep an eye on this small company with a current market cap of about $20 million whose stock has rallied over 350% this year (as of Sep. 5) as it expands its presence in industries worth billions of dollars. Featured photo by Narupon Promvichai from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:58 AM Eastern Daylight Time

Image
Article thumbnail News Release

Casa Blui Launches New Range of Home Wellness Products

Rev Up Marketers

Casa Blui is excited to announce the launch of its latest range of home wellness products, redefining the luxury spa experience for households. This collection includes luxury hot tubs, saunas, cold plunges, outdoor kitchens, and fire pits, each designed with meticulous European craftsmanship and cutting-edge technology. The new range aims to bring a touch of luxury and relaxation into every home, allowing customers to create their own personal spa retreats. Each product is carefully crafted to offer a seamless blend of style, comfort, and functionality, ensuring a high-quality experience that enhances well-being. “We are thrilled to launch this new collection, which reflects our dedication to innovation and excellence,” said the CEO of Casa Blui. “Our products are designed to transform home spaces into serene wellness sanctuaries, providing our customers with the ultimate relaxation and rejuvenation experience.” This launch is a key milestone in Casa Blui mission to make premium wellness products accessible to all, empowering customers to create their own luxurious holistic wellness environments at home. Discover the new range today and elevate your home spa experience to a new level. About Casa Blui Casa Blui is committed to delivering top-quality home spa solutions, from luxurious hot tubs to advanced spa accessories. With a focus on innovation, safety, and customer satisfaction, Designer Home Spas remains a trusted industry leader. Contact Details Casa Blui Andrei Newman +1 305-701-4029 support@casablui.com Company Website https://casablui.com/

September 10, 2024 08:57 AM Eastern Daylight Time

Image
Article thumbnail News Release

Brand Engagement Network (NASDAQ: BNAI) Expands Global Footprint As It Secures $5.9M in Private Placement Financing And Enters $50M Standby Equity Purchase Agreement

Benzinga

By Anthony Termini, Benzinga Brand Engagement Network (NASDAQ: BNAI) (BEN), which creates artificial intelligence (AI) solutions for consumer engagement using human-like avatars as the interface to communicate with customers, hit multiple milestones recently Early in September, the company entered into an agreement with IntelliTek Health. IntelliTek Health is a subsidiary of SmarTek21 and creates solutions for virtual assistants that interact with medical patients. It develops clinical and patient-facing tools and focuses exclusively on bringing AI-enabled productivity and services to the healthcare industry. What The IntelliTek Deal Means For BEN The agreement grants BEN a worldwide license to provide AI-driven solutions to support healthcare operations and optimize patient engagement throughout the United States, Australia, New Zealand, India and Europe. Together, BEN and IntelliTek will offer a suite of AI-driven healthcare solutions to support and execute a broad range of tasks and operations that serve both medical professionals and patients. The agreement is intended to seek synergies in the strengths and solutions of both companies. Brand Engagement Network will combine its Healthcare AI Assistant, Sandy – which serves as a direct interface resource for patients – with IntelliTek’s Personal Virtual Assistant (PVA). Sandy can help patients schedule appointments and obtain up-to-date information on prescription drugs. The IntelliTek PVA is part of a collaboration with Samsung Mobile Solutions and other leading U.S. and multinational telecommunications companies. The deal also combines BEN’s AI technology with IntelliTek’s Clinical Virtual Assistant (CVA). The CVA is specifically designed for clinical teams looking to reduce their administrative burden. BEN reports that it has been shown to improve administrative efficiency by up to 50%, creating the opportunity to improve patient throughput by up to 17%. Another solution rolled into the agreement is IntelliTek’s hands-free and voice-enabled Document Search AI. This device-agnostic tool can quickly and securely search for and retrieve specific medical information in real time from many different document formats sourced from a wide variety of different repositories. Martyn Molnar, Chief Executive of Products at Intellitek Health, says that the “cooperation with BEN will enable both companies to offer a comprehensive suite of AI solutions for the healthcare industry, which is experiencing critical challenges surrounding workforce and resource availability.” “We’re proud to have found a like-minded ally in IntelliTek, as we both strive to elevate patient experiences and healthcare professional productivity with innovative AI technology,” added Paul Chang, BEN’s CEO. The two executives believe that together the platforms can serve as an end-to-end suite of solutions that offers continuous support to improve healthcare access and outcomes. They believe the collaboration will help each company broaden its customer base. It is expected that the agreement will expand the reach of both companies’ solutions to a larger number of healthcare providers and patients and increase access to life-saving AI technology. IntelliTek delivers highly curated products that automate over 2 billion interactions reaching more than 600 million global users, reports the company. The company and its parent, SmarTek21, ensure seamless connectivity of more than 100 pre-built integrations to support AI-driven solutions. Together they provide intelligent workflow automation across healthcare, telecommunications, aviation, finance and global eCommerce platforms. The healthcare industry represents one of BEN’s primary target markets. The company’s full-stack platform includes front-end, middleware and back-end functionality through scalable, customizable solutions that it says are fully optimized to deliver superior customer experiences, productivity and performance. New Financing Transactions Prior to the IntelliTek Health announcement, BEN completed two investment transactions that provide the company with increased financial flexibility and access to capital to support its ongoing strategic growth initiatives. In August, BEN closed a $5.9 million private placement, which will provide funding to the company on a monthly basis through the first quarter of 2025. The investment was supported by a group of BEN’s existing stockholders, who agreed to purchase nearly 1.2 million shares of common stock. The transaction was consummated at a price per share that was materially above the trading price of the company’s common stock at the time. For each share purchased, investors received an additional share of common stock from certain other existing stockholders. In exchange for transferring those shares, certain transferring stockholders received an aggregate of 960,000 warrants to purchase shares of BEN’s common stock at $5.00 per share. Concurrent with the private placement, BEN also entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The SEPA provides BEN with the ability, but not the obligation, to cause Yorkville to purchase up to the aggregate amount of $50 million of BEN common stock. The SEPA is intended to provide BEN with access to capital on an as-needed basis to fund its business plan as it seeks to execute its growth and revenue strategies. The SEPA cannot be used until a registration statement is declared effective by the Securities and Exchange Commission. These two transactions are intended to help the company expand market validation and scale production of its human-like conversational AI assistants. For more information about BEN, please visit www.beninc.ai. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:55 AM Eastern Daylight Time

Image
1 ... 3738394041 ... 3747